Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs

Inflammatory Bowel Diseases

Volumn 9, Issue 2, 2003, Pages 87-97

  Sydora, Beate C ^a   Tavernini, Michele M ^a   Wessler, Andreas ^a   Jewell, Lawrence D ^a   Fedorak, Richard N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bacteria; Colitis; Crohn's disease; Inflammatory bowel disease; Interleukin 10; Tolerance

Indexed keywords

BACTERIAL ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BACTERIAL COLONIZATION; CELL STIMULATION; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROCOLITIS; GERMFREE ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INFLAMMATION; INTERFERON PRODUCTION; INTESTINE FLORA; INTESTINE INJURY; MICROFLORA; MOUSE; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN CELL;

ANIMALS; ANTIGENS, BACTERIAL; COLONY COUNT, MICROBIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERFERON TYPE II; INTERLEUKIN-10; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037348386     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200303000-00002     Document Type: Review

References (35)

1. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995;24:475-507.
2. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol 1997;148: 567-76.
3. Onderdonk AB, Hermos JA, Dzink JL, et al. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521-6.
4. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-62.
5. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991;32: 1071-5.
6. Aranda R, Horgan K. Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin Gastrointest Dis 1998;9:2-9.
7. Madsen KL, Doyle JS, Tavernini MM, et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 2000;118:1094-105.
8. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-41.
9. Onderdonk AB, Franklin ML, Cisneros RL. Production of experimental ulcerative colitis in gnotobiotic guinea pigs with simplified microflora. Infect Immun 1981;32:225-31
10. Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994;180:2359-64.
11. Aranda R, Sydora BC, McAllister PL, et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RB high T cells to SCID recipients. J Immunol 1997;158: 3464-73.
12. Dianda L, Hanby AM, Wright NA, et al. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-7.
13. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31
14. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999;67: 2969-74.
15. Tabaqchali S, O'Donoghue DP, Bettelheim KA. Escherichia coli antibodies in patients with inflammatory bowel disease. Gut 1978; 19:108-13.
16. Hazenberg MP, de Visser H, Bras MJ, et al. Serum antibodies to peptidoglycan-polysaccharide complexes from the anaerobic intestinal flora in patients with Crohn's disease. Digestion 1990;47: 172-80
17. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) [see comments]. Clin Exp Immunol 1995;102: 448-55.
18. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol 1997;148:589-94
19. Duchmann R, Schmitt E, Knolle P, et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
20. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards Enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans [see comments]. Gut 1999;44:812-8.
21. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995;3:171-4.
22. Davidson NJ, Fort MM, Muller W, et al. Chronic colitis in IL-10-/-mice: insufficient counter regulation of a Th1 response. Int Rev Imumnol 2000;19:91-121.
23. Asseman C, Powrie F. Interleukin 10 is a growth factor for a population of regulatory T cells. Gut 1998;42:157-8.
24. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 2001;166: 3008-18.
25. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
26. Madsen KL, Malfair D, Gray D, et al. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 1999;5:262-70.
27. Adkins B, Du RQ. Newborn mice develop balanced Th1/Th2 primary effector responses in vivo but are biased to Th2 secondary responses. J Immunol 1998;160:4217-24.
28. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity in neonatal mice. Science 1996;271:1728-30.
29. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T cells and, upon subsequent immunization, induce their immune deviation: implications for antibody versus T cell-mediated autoimmunity. J Exp Med 1996;183:1613-21.
30. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993;11:165-90
31. Rizzo LV, Morawetz RA, Miller-Rivero NE, et al. IL-4 and IL-10: are both required for the induction of oral tolerance. J Immunol 1999;162:2613-2622.
32. Khoo UY, Proctor IE, Macpherson AJ. CD4+ T cell downregulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. J Immunol 1997;158:3626-34.
33. Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-62.
34. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996;98:1010-20.
35. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001;166:3789-96.